PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced it will present new data on its lead product candidate INO-3107, a potential treatment for Recurrent Respiratory Papillomatosis (RRP), at several upcoming scientific conferences. The company has begun the rolling submission of its Biologics License Application (BLA) for INO-3107 and expects to complete the filing in the second half of 2025, with the goal of U.S. Food and Drug Administration acceptance by year-end.
Presentations will highlight long-term efficacy data of INO-3107 in treating HPV-6 and HPV-11-related RRP. The company will also share findings from its Stroke Registrational Program and other ongoing studies at global forums including the American Academy of Otolaryngology Annual Meeting in Indianapolis, the World Vaccine Congress Europe in Amsterdam, the European Society for Medical Oncology Congress in Berlin, the International Papillomavirus Society Conference in Bangkok, and the International Society for Vaccines Congress in South Africa.
In addition to RRP research, INOVIO will present developments in next-generation DNA medicine technology. This includes early-stage data on a DNA-encoded monoclonal antibody (DMAb) candidate and new preclinical data describing the potential for DNA-encoded protein technology (DPROT) to address Hemophilia A. Presentations are scheduled for the European Society of Gene and Cell Therapy Congress in Seville, the World Vaccine Congress Europe, the World Orphan Drug Congress in Amsterdam, and the World Federation of Hemophilia Global Forum in Montreal.
Abstracts from these presentations will be available on INOVIO’s website following the events.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.